Caris holder plans $2.6M sale of 100,000 shares

Caris Life Sciences, Inc. (CAI) is the issuer of common stock that the GEORGE H POSTE REVOCABLE TRUST plans to sell under Rule 144.

Rhea-AI Filing Summary

Caris Life Sciences, Inc. (CAI) is the issuer of common stock that the GEORGE H POSTE REVOCABLE TRUST plans to sell under Rule 144. The notice covers a proposed sale of 100,000 shares of common stock, to be sold through Morgan Stanley Smith Barney LLC Executive Financial Services on NASDAQ.

The shares to be sold were acquired from the issuer through previously exercised options. The filing cites an aggregate market value of $2,606,320.00 for these 100,000 shares and lists total shares of this class outstanding as 282,595,186. The proposed sale date is 08/11/2025, with payment in cash.

Over the prior three months, George Poste reported additional sales of Caris Life Sciences common stock: 30,000 shares on 08/07/2026 for $642,633.00, and 20,000 shares on 08/03/2026 for $325,000.00. The notice is signed by George Poste, Trustee.

Key Figures

Shares to be sold under Rule 144: 100,000 shares of common stock Aggregate market value of shares to be sold: $2,606,320.00 Shares outstanding: 282,595,186 shares +3 more

6 metrics

Shares to be sold under Rule 144 100,000 shares of common stock Proposed sale by GEORGE H POSTE REVOCABLE TRUST

Aggregate market value of shares to be sold $2,606,320.00 Value for 100,000 shares of common stock in the Rule 144 notice

Shares outstanding 282,595,186 shares Total outstanding common shares of this class

Proposed sale date for Rule 144 shares 08/11/2025 Planned sale date for 100,000 shares acquired via previously exercised options

Recent sale 1 30,000 shares for $642,633.00 Common shares sold on 08/07/2026 by George Poste

Recent sale 2 20,000 shares for $325,000.00 Common shares sold on 08/03/2026 by George Poste

Key Terms

Rule 144, Former Affiliate, Previously Exercised Options

3 terms

Rule 144 regulatory

"See the definition of "person" in paragraph (a) of Rule 144."

Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.

Former Affiliate regulatory

"Former Affiliate 144: Securities Information"

Previously Exercised Options financial

"Common | 08/11/2025 | Previously Exercised Options | Issuer"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the Form 144 filing mean for Caris Life Sciences, Inc. (CAI)?

The filing reports that the GEORGE H POSTE REVOCABLE TRUST plans to sell 100,000 shares of Caris Life Sciences common stock under Rule 144. It is a notice of a potential resale by an affiliated holder and does not itself change the company’s capital structure.

How many CAI shares are covered by this Rule 144 notice?

The Rule 144 notice covers a proposed sale of 100,000 shares of Caris Life Sciences common stock. The filing also states an aggregate market value of $2,606,320.00 for these shares and lists total shares outstanding of this class as 282,595,186.

Who is selling Caris Life Sciences (CAI) shares under this Form 144 and through whom?

The GEORGE H POSTE REVOCABLE TRUST, with George Poste as Trustee, is the selling holder. The planned sale of 100,000 shares of CAI common stock is to be executed through Morgan Stanley Smith Barney LLC Executive Financial Services on NASDAQ.

When were the Caris Life Sciences (CAI) shares to be sold acquired, and how?

The 100,000 CAI shares covered by this notice were acquired from the issuer through previously exercised options. The planned sale date for these shares is listed as 08/11/2025, with payment specified as cash.

What prior CAI stock sales are disclosed in the past three months?

The filing discloses that George Poste sold 30,000 shares of Caris Life Sciences common stock on 08/07/2026 for $642,633.00, and 20,000 shares on 08/03/2026 for $325,000.00, during the three months preceding the notice.

How many Caris Life Sciences (CAI) shares are outstanding according to this filing?

The filing states that there are 282,595,186 shares of Caris Life Sciences common stock outstanding. This figure provides context for the 100,000 shares covered by the Rule 144 notice as a small portion of the total outstanding shares.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/24/2026 - 04:29 PM EDT Accepted by SEC EDGAR 08/24/2026 - 04:29 PM EDT Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001180770
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	CARIS LIFE SCIENCES, INC.
SEC File Number	001-42706
Address of Issuer	750 W JOHN CARPENTER FREEWAY SUITE 800 IRVING TEXAS 75039
Phone	866-771-8946
Name of Person for Whose Account the Securities are To Be Sold	GEORGE H POSTE REVOCABLE TRUST
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Former Affiliate

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	100000	2606320.00	282595186	08/24/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	08/11/2025	Previously Exercised Options	Issuer			100000	08/11/2025	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
George Poste 750 W JOHN CARPENTER FREEWAY SUITE 800 IRVING TX 75039	Common	08/07/2026	30000	642633.00
George Poste 750 W JOHN CARPENTER FREEWAY SUITE 800 IRVING TX 75039	Common	08/03/2026	20000	325000.00

144: Remarks and Signature

Remarks
Date of Notice	08/24/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ George Poste, Trustee
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)